In the exploration of combination TRAIL/verticillin A therapy on high grade colon carcinoma, Liu et al. were able to reduce the verticillin A dosage from 30–122 nM to 10 nM11, thereby successfully sensitizing tumor cells to TRAIL treatment. This evidence concerns the gene TNFSF10 and colon carcinoma.